Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 29 • 2019 ACR/ARP Annual Meeting
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro
Bohdan Harvey¹ and Zehra Kaymakcalan ¹, ¹AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Therapeutic anti-TNF biologic agents can be distinct in their structure and/or in their binding to TNF. Whether these differences affect the functional properties of…
Abstract Number: 112 • 2019 ACR/ARP Annual Meeting
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Sushmita Chakraborty ¹, Ranjan Gupta ², Rinkee Kumari ¹ and Dipendra Kumar Mitra¹, ¹All India Institute of Medical Sciences, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 296 • 2019 ACR/ARP Annual Meeting
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Diana Vossen ¹, Valentin Schaefer², Florian Recker ³, Isabelle Geffken ⁴, Eva Matuschek ⁵ and Wolfgang Hartung ⁶, ¹Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ²Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn, Bonn, Germany, ³1. Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn and 2. Department for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ⁴Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St.Elisabeth Hospital, Düsseldorf, Germany, ⁵Department for Internal Medicine, Dreifaltigkeits-Krankenhaus Wesseling, bonn, Germany, ⁶Rheumatology und clinical Immunology, Asklepios Klinik, 93077 Bad Abbach, Bad Abbach, Germany
Background/Purpose: Musculoskeletal ultrasound is an important imaging method in the diagnosis of arthritis, especially rheumatoid arthritis (RA). The prevalence of elbow joint arthritis in RA…
Abstract Number: 450 • 2019 ACR/ARP Annual Meeting
ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography
Julien Grosse¹, Edem Allado ¹, Camille Roux ¹, Audrey Pierreisnard ², Marion Couderc ³, Isabelle Clerc-Urmès ¹, Thomas Remen ¹, Eliane Albuisson ⁴, Marcelo De Carvalho ¹, Isabelle Chary-Valckenaere ⁴ and Damien Loeuille ⁵, ¹Centre Hospitalier Universitaire de Nancy, Nancy, France, ²APHP, Paris, France, ³CHU G.Montpied, Clermont Ferrand, France, ⁴Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ⁵Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France
Background/Purpose: Several studies have shown that ACPA-positive (ACPA+) patients were more likely to develop erosive disease on radiography (RX) than ACPA-negative (ACPA-) patients, but it…
Abstract Number: 477 • 2019 ACR/ARP Annual Meeting
Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients
Catia Duarte¹, Eduardo Santos ², Eirik Kristianslund ³, Turid Heiberg ⁴, Maarten de Wit ⁵, Maxime Dougados ⁶, Tore Kvien ⁷, Laure Gossec ⁸ and Jose Pereira da Silva ⁹, ¹Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁴Department for Research and Education, Oslo University Hospital, Oslo, Norway, ⁵Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁶Cochin Hospital, Paris, France, ⁷Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal
Background/Purpose: Patient Acceptable Symptom State (PASS) represents the maximum level of symptom intensity that a patient considers acceptable. Control of disease activity is associated with the…
Abstract Number: 528 • 2019 ACR/ARP Annual Meeting
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Daniel Furst ², Erin Connolly-Strong ³, Jingyu Liu ³, Julie Zhu ³ and Richard Brasington ⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Washington University School of Medicine in St Louis, St Louis, MO
Background/Purpose: Persistently active rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and bone loss.1 Although short-term administration of corticosteroids (CSs) is recommended…
Abstract Number: 833 • 2019 ACR/ARP Annual Meeting
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne Lee¹, Fengxin Lu ², Joshua Colls ², Meredith Murray ², Dong Suh ², Jing Song ³, Julia (Jungwha) Lee ⁴, Dorothy Dunlop ⁴ and Daniel Solomon ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, ²Brigham and Women's Hospital, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Treat to target (TTT) is an effective strategy to improve outcomes in rheumatoid arthritis (RA). However, barriers to TTT include frequent clinic visits, poor…
Abstract Number: 932 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Kentaro Torii ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 1156 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis
Julian Barahona-Correa¹, Jorge Florez ¹, Mateo Rodriguez ², Karen Ramirez ³, Paul Mendez-Patarroyo ¹, Paola Coral-Alvarado ¹ and Gerardo Quintana-López ¹, ¹Reumavance Group, section of Rheumatology, Fundacion Santa Fe de Bogota University Hospital, Bogota DC, Distrito Capital de Bogota, Colombia, ²School of Medicine, Universidad de Los Andes, Bogota, Distrito Capital de Bogota, Colombia, ³School of Medicine, Universidad Nacional de Colombia, Bogota DC, Distrito Capital de Bogota, Colombia
Background/Purpose: Rheumatoid Arthritis (RA) generates high impact on patients and healthcare systems. Adequate control of disease activity depends to a large extent on the access…
Abstract Number: 1342 • 2019 ACR/ARP Annual Meeting
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Joseph Patrick Michele Blair¹, Cecilie Bager ², Man Hung Eric Tang ², Morten Karsdal ³, Anne Bay-Jensen ⁴ and Søren Brunak ⁵, ¹Univeristy of Copenahgen, Copenhagen, Denmark, ²Nordic Bioscience ProScion, Copenhagen, Denmark, ³Nordic Bioscience, Copenhagen, Denmark, ⁴Nordic Bioscience, Herlev, Denmark, ⁵Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease with a fluctuating course of disease activity and progression. Although treatments have improved substantially in recent…
Abstract Number: 1369 • 2019 ACR/ARP Annual Meeting
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
Ji-Won Kim¹, Jin-Sun Kong ², Youngjae Park ³ and Wan-Uk Kim ³, ¹Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ²Catholic University of Korea, College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Previously, we demonstrated the direct pro-inflammatory role of the vascular endothelial growth factor (VEGF) and the placenta growth factor (PlGF), and angiogenic factors in…
Abstract Number: 1396 • 2019 ACR/ARP Annual Meeting
Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Jennie Best ³, Steve Zlotnick ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Understanding persistence of biologic therapies and factors associated with discontinuation can help inform treatment decisions for patients with rheumatoid arthritis (RA). We sought to…
Abstract Number: 1434 • 2019 ACR/ARP Annual Meeting
Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept
Nobunori Takahashi¹, Toshihisa Kojima ¹, Kenya Terabe ¹, Shuji Asai ¹ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Japanese post-marketing surveillance (PMS) data demonstrated that effectiveness of abatacept in rheumatoid arthritis (RA) patients with previous biologics treatment (bio-switch) was significantly lower than…
Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Thierry Dervieux¹, Joel Kremer ², John Conklin ¹, Kelley Brady ¹, Roberta Alexander ¹, Tyler O'Malley ³, Jing Shi ¹, Claudia Ibarra ¹, Michael Mahler ⁴, Michael Weinblatt ⁵ and Arthur Weinstein ¹, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Exagen, Oceanside, CA, ⁴Inova Diagnostics, San Diego, CA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].